Christophe Corpechot, Sara Lemoinne, Pierre-Antoine Soret, Bettina Hansen, Gideon Hirschfield, Aliya Gulamhusein, Aldo J Montano-Loza, Ellina Lytvyak, Albert Pares, Ignasi Olivas, John E Eaton, Karim T Osman, Christoph Schramm, Marcial Sebode, Ansgar W Lohse, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Nora Cazzagon, Alessandra Zago, Francesco Paolo Russo, Annarosa Floreani, Nadir Abbas, Palak Trivedi, Douglas Thorburn, Francesca Saffioti, Laszlo Barkai, Davide Roccarina, Vicenza Calvaruso, Anna Fichera, Adèle Delamarre, Natalia Sobenko, Alejandra Maria Villamil, Esli Medina-Morales, Alan Bonder, Vilas Patwardhan, Cristina Rigamonti, Marco Carbone, Pietro Invernizzi, Laura Cristoferi, Adriaan van der Meer, Rozanne de Veer, Ehud Zigmond, Eyal Yehezkel, Andreas E Kremer, Ansgar Deibel, Tony Bruns, Karsten Große, Aaron Wetten, Jessica Katharine Dyson, David Jones, Jérôme Dumortier, Georges-Philippe Pageaux, Victor de Lédinghen, Olivier Chazouillères, Fabrice Carrat
BACKGROUND AND AIMS: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (xULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. APPROACH AND RESULTS: We performed a retrospective cohort study of 1,047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria...
July 3, 2023: Hepatology: Official Journal of the American Association for the Study of Liver Diseases